What Syncona Partners LLP does

Syncona Partners LLP is the operating identity associated with Syncona Limited, a London-listed (LSE: SYNC) closed-ended life sciences investment company founded in 2012 and headquartered in London, with a registered office in Guernsey. The firm creates, builds, and scales 20-25 life science businesses across development stage, modality, and therapeutic area, targeting transformational treatments in areas of high unmet need. It invests in or builds companies itself (as founding investor of Beacon Therapeutics and Quell Therapeutics, acquirer of Freeline/Spur Therapeutics and AGTC), and operates the Syncona Accelerator programme (via Slingshot Therapeutics) to advance de-risked academic programmes. Its portfolio spans commercial-stage (Autolus Therapeutics, with FDA/MHRA-approved AUCATZYL CAR-T therapy), late-stage clinical (Beacon, Spur), clinical (Quell, Resolution, iOnctura, Anaveon, Mosaic, Purespring), and pre-clinical (OMass, Yellowstone, ALTx, Forcefield, Kesmalea, Re-Aim) companies across cell therapy, gene therapy, immuno-oncology, regenerative medicine, and small-molecule discovery.

The company's revenue mechanics are not product-driven; as a closed-ended investment vehicle, financial performance is measured by Net Asset Value (£1.0bn / 171p per share as at 31 March 2026) and the firm targets returning at least £250m to shareholders through portfolio exits via M&A and liquidity events. The investment manager, Syncona Investment Management Limited (FCA-authorised, England), sources proprietary deal flow from world-class academic founders via partnerships with institutions such as the University of Oxford, Francis Crick Institute, University of Manchester, and Cancer Research Horizons, and typically syndicates with co-investors (Oxford Science Enterprises, Forbion, TCGX, Advent Life Sciences, Sanofi Ventures, GV, Northpond). Distribution is via LSE public-market trading and IR communications (RNS, email alerts, annual reports). With 11-50 employees and £81m deployed annually — 84% of which into late-stage and clinical assets — Syncona operates a capital-light investment and company-creation model distinct from traditional venture capital GPs.

Name

Syncona Partners LLP

Legal name

Syncona Limited

Website

https://synconaltd.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Syncona Partners LLP operates as Syncona Limited, a London-listed (LSE: SYNC) life sciences investment company that creates, builds, and scales 20-25 therapeutic companies across cell therapy, gene therapy, and oncology, targeting shareholder returns via portfolio exits.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Investment Returns and NAV Growth: Syncona generates returns through M&A and liquidity events from its portfolio companies, with the goal of maximizing shareholder value through the appreciation of its net asset value. The company aims to return at least £250 million to shareholders from private company exits.
2. Portfolio Company Value Creation: Creating, building and scaling life science companies to deliver transformational treatments to patients, with returns generated through eventual exits via M&A or public listings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Syncona is a London-listed life sciences investment company that creates, builds, and scales life science businesses to deliver transformational treatments to patients. The company deploys patient capital into a diversified portfolio of 20-25 companies across development stages, modalities, and therapeutic areas, with a focus on cell and gene therapy. Returns are generated through M&A exits, liquidity events, and net asset value (NAV) appreciation, with a stated goal of returning at least £250 million to shareholders from private company exits.

Product overview

Syncona Limited is a London-listed life sciences investment company that creates, builds, and scales life science companies to deliver transformational treatments to patients. The company maintains a diversified portfolio of 20-25 globally leading life science businesses across development stages and therapeutic areas. The portfolio spans from commercial-stage companies like Autolus Therapeutics (with FDA/MHRA-approved CAR-T therapy AUCATZYL) to late-stage clinical companies including Beacon Therapeutics (gene therapy for eye diseases) and Spur Therapeutics (gene therapy for Gaucher disease), to clinical-stage companies focused on cell therapies (Quell Therapeutics, Resolution Therapeutics), immuno-oncology (Anaveon), and pre-clinical companies across various modalities including gene therapy, small molecules, and bispecific antibodies. Syncona provides capital, operational expertise, and long-term investment horizon to support portfolio companies through clinical development toward M&A and liquidity events.

Differentiator

Problem solved

Functional benefit

Products and services

• SYNC Listed Equity (Investment Vehicle)
• Life Sciences Investment and Company Creation
• AUCATZYL (obecabtagene autoleucel)

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature1 record

Partnerships

Three partnerships are on record, tiered core and flagship.

• The Francis Crick InstitutecoreStrategic or Co-development Partner · 6 February 2026ALTx Therapeutics launched as spin-out from The Francis Crick Institute with £12.55 million initial funding from Syncona, the Crick, and Cancer Research Horizons, based on pioneering research by Simon Boulton on ALT-mediated cancer cell immortalisation.
• University of ManchestercoreStrategic or Co-development Partner · 14 November 2024Slingshot Therapeutics in-licensed its first programme Apini from The University of Manchester, founded on innovative work of Professor Sam Butterworth in inflammatory diseases.
• AstraZenecaflagshipStrategic or Co-development Partner · 1 June 2023Strategic collaboration to develop, manufacture and commercialize autologous, engineered Treg cell therapies for Type 1 Diabetes and Inflammatory Bowel Disease. Quell received $85 million upfront and is eligible for over $2 billion in development and commercialization milestones plus tiered royalties. AstraZeneca exercised option for IBD candidate in 2025, triggering $10 million payment.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• International Biotechnology Trust: LSE-listed investment trust focused on quoted and unquoted biotechnology and life sciences companies globally. Same investment-trust structure as Syncona, with public market liquidity and similar exposure to clinical-stage biotech risk/return profile.
• BB Healthcare Trust: LSE-listed investment trust investing in global listed healthcare equities with a concentration in mid- and large-cap pharma/biotech. Closely comparable listed vehicle delivering healthcare exposure through a disciplined portfolio approach.
• Worldwide Healthcare Trust: LSE-listed investment trust providing global healthcare and biotech equity exposure across market caps and geographies. Same structural format as Syncona — public-listed fund — with comparable NAV/discount dynamics for investors.
• Polar Capital Global Healthcare Growth & Income Trust: LSE-listed investment trust managed by Polar Capital focused on global healthcare equities with a growth and income mandate. Direct structural peer to Syncona's listed-fund format with healthcare/biotech asset focus.
• Arix Bioscience (formerly): Was a London-listed life sciences investment company that built and developed biotech businesses — historically the closest structural and strategic analog to Syncona before being wound down. Same company-creation-and-build model in life sciences.
• RTW Investments: US-based specialist life sciences and biotech investment manager running public and private strategies. Comparable in deploying patient capital across biotech development stages with deep scientific due diligence.

Broad incumbents

• OrbiMed Advisors: One of the world's largest healthcare-dedicated investment firms across venture, growth, and public equity strategies. A broader incumbent serving the same biotech capital-needs as Syncona but at materially larger scale and across all stages.
• Baker Bros. Advisors: US biotech-focused investment advisor managing long-only and concentrated public/private life sciences strategies. Comparable science-driven, concentrated approach to identifying transformational biotech opportunities.
• Atlas Venture: Early-stage biotech venture capital firm that builds companies from academic science — directly analogous to Syncona's spinout model (e.g. Yellowstone from Oxford, ALTx from Crick). Operates as fund manager rather than permanent capital.
• ARCH Venture Partners: Large US venture firm focused on founding and building biotech companies from frontier science, including cell/gene therapy. Comparable in creating companies around transformational science but as a multi-fund venture firm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments53 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syncona Partners LLP